Retinal Regeneration

Demonstrated components (today): regeneration cannot happen into tissue that is dying out from under it — it has to occur into living retina. The cells that must be kept alive are well defined: the photoreceptors that still sense light, the ganglion cells that still carry the signal, and above all the Müller glia that will perform the regeneration itself. The full protection toolkit is established and covered in Vision Preservation.

The capability being built toward: preserving that living substrate — including the repair cells regeneration depends on — long enough for regrowth to occur. When fully built, the aim is to hold the surviving retina and its Müller glia alive as the foundation every later regeneration step builds on. The protective biology is demonstrated; applying it specifically to safeguard the cells and repair cells that regrowth requires is the direction here.

Endogenous neuroprotection, oxidative-stress and metabolic defense, neurotrophic support, and the survival of photoreceptors, ganglion cells, and the Müller glia that perform regeneration — because regeneration depends on keeping those cells alive long enough to rebuild.

Sustained neurotrophic support keeps photoreceptors alive in people. Paul Sieving and the National Eye Institute, using an encapsulated-cell implant that releases ciliary neurotrophic factor (CNTF) inside the eye, showed structural preservation of photoreceptors in human retinal-degeneration studies — proof that supporting the retina’s own survival signals slows the loss of the very cells regeneration depends on (though delivered today by an implant, an honest boundary until it can be given noninvasively).

The eye’s own antioxidant switch shields its neurons. Elia Duh’s lab at Johns Hopkins University, using Nrf2-knockout mice and Nrf2 activators in retinal models, showed that the Nrf2 pathway turns on the retina’s own protective genes and defends photoreceptors and ganglion cells against the oxidative stress that degenerates them — keeping more of the substrate alive for regrowth.

Controlling the body protects the retina. The NIH-sponsored DCCT Research Group, in a randomized trial of people with type 1 diabetes, showed that intensive blood-sugar control cut the risk of developing diabetic retinopathy by about 76% — the same grounded, body-wide protection detailed in Vision Preservation.

Research & institutions: Paul Sieving and the National Eye Institute, Neurotech Pharmaceuticals, Elia Duh’s lab at Johns Hopkins University, the NIH DCCT/EDIC Research Group, the Schepens Eye Research Institute at Mass Eye and Ear, Harvard Medical School, the Doheny Eye Institute, the Wilmer Eye Institute at Johns Hopkins, the University of California San Diego, University College London, the Glaucoma Research Foundation, the Foundation Fighting Blindness, the Department of Defense Vision Research Program (CDMRP), and the broader retinal-neuroprotection field.

Demonstrated components (today): the signals that reawaken the retina’s own repair cells — and, when needed, replacement cells — are known, but getting them past the ocular surface to the Müller glia and photoreceptor layer at the back of the eye is a science in its own right. Noninvasive routes exist as real directions: eye drops, topical biologics, and needle-free carriers, rather than repeated injections or surgery.

The capability being built toward: delivering regeneration so it can be received without creating new harm. When fully built, it would reach the back of the eye without injections, without surgery, and without new injury. The biology of regeneration is only half the story; the harm-free delivery half is the frontier — the noninvasive carriers are real today, and routing them safely to the Müller glia and photoreceptors is the direction.

Named noninvasive routes for reaching the retina: eye drops and topical biologics, mucus- and gel-penetrating nanoparticle carriers, penetration-enhancing and sustained-release depots, and non-viral gene-regulatory carriers — engineered to move proteins, brake-release signals, and gene-regulatory payloads past the ocular surface toward the back of the eye without a needle. An active delivery-science direction, not yet a finished public solution.

A regenerative biologic can already be delivered as a drop. Alessandro Lambiase and colleagues developed recombinant human nerve-growth-factor eye drops (cenegermin, FDA-approved 2018) that heal the ocular surface and regrow corneal nerves with no needle and no operation — proof a regenerative signal can rebuild living tissue noninvasively.

Reaching the back of the eye without an injection. Justin Hanes and Jung Soo Suk at the Johns Hopkins Center for Nanomedicine engineered mucus- and gel-penetrating nanoparticle carriers that move large molecules toward the retina in animal models — challenging the assumption that the retina can only be reached by injection.

One dose that keeps working. Robert Langer’s laboratory at the Massachusetts Institute of Technology pioneered sustained-release depots that deliver a protein steadily for months from a single placement. Today’s reawakening and replacement signals are still delivered by intravitreal or subretinal injection — an honest current boundary the noninvasive routes are built to replace.

Research & institutions: Alessandro Lambiase at Sapienza University of Rome, Justin Hanes and Jung Soo Suk at the Johns Hopkins Center for Nanomedicine, Robert Langer at the Massachusetts Institute of Technology, the National Eye Institute, David Gamm at the University of Wisconsin–Madison, Thomas Reh at the University of Washington, and the broader ocular drug-delivery field.

Demonstrated components (today): the retina is already a regenerating tissue — just a partial one. Every day, photoreceptors rebuild their light-sensing tips, and the support layer beneath them clears the worn pieces and recycles what they need. This daily self-repair is proven and ongoing in every healthy retina.

The capability being built toward: learning from that renewal and building on it — understanding exactly how the retina repairs itself each day, protecting and strengthening those systems so they keep working with age, and extending the same self-repair biology so more of the retina can benefit. When fully built, it would widen this proven daily renewal into a foundation for deeper regeneration. The partial self-repair is real and demonstrated today; broadening it across more of the retina, and sustaining it through aging, is the frontier.

Photoreceptor outer-segment renewal and shedding, retinal-pigment-epithelium (RPE) phagocytosis and the visual cycle, and the daily clearance and recycling that keep photoreceptors functioning — the retina’s built-in maintenance and self-renewal.

The discovery that photoreceptors renew themselves. Richard Young’s autoradiography studies first revealed that photoreceptors continuously build new light-sensing outer-segment discs at their base and shed worn ones from the tip — a complete, daily renewal of the light-sensing structure that the healthy retina performs for life.

The support layer clears and recycles for them. Richard Young and Dean Bok showed that the retinal pigment epithelium engulfs the shed photoreceptor tips each day in a precise rhythm, clearing and recycling them; this daily phagocytosis is essential, and when it fails, photoreceptors die.

The retina recycles the molecule of vision. George Wald at Harvard University, in Nobel Prize–winning work, traced how the retina continuously regenerates the light-sensitive pigment photoreceptors need — recycling vitamin A between the photoreceptors and the support layer — another of the retina’s built-in self-renewal systems, and grounded proof that the retina rebuilds parts of itself every day.

Research & institutions: the National Eye Institute, the foundational work of Richard Young and Matthew LaVail at the University of California San Francisco, Dean Bok at the UCLA Jules Stein Eye Institute, George Wald’s visual-cycle research at Harvard University, the Wilmer Eye Institute at Johns Hopkins, the University of Washington, the Schepens Eye Research Institute at Mass Eye and Ear, Moorfields Eye Hospital and University College London, the Foundation Fighting Blindness, Stanford University, the Doheny Eye Institute, and the broader photoreceptor- and RPE-biology field.

Demonstrated components (today): the retina holds Müller glia — support cells spanning its full thickness that keep a latent stem-cell character. In fish, these are the very cells that fully regrow an injured retina; in humans they are present but held quiet. That fish regeneration is demonstrated, and the human cells’ latent capacity is established. Shared with neuroregeneration.

The capability being built toward: this is the heart of retinal regeneration — reawakening the retina’s own Müller glia to divide and make new retinal neurons, regrowing sight from the retina’s own cells rather than replacing them. When fully built, it would let the human retina regrow itself the way a fish’s does. The repair cells and the fish precedent are real today; reliably reawakening them in the human retina is the frontier.

Müller-glia reprogramming, proneural transcription factors (Ascl1 and others), endogenous retinal-progenitor activation, and de-novo photoreceptor and neuron genesis from the retina’s own glia — demonstrated in animals, not yet a finished human solution.

Nature already regrows retinas — and we know which cell does it. Pamela Raymond and Daniel Goldman at the University of Michigan, working in zebrafish, showed that after injury the Müller glia re-enter the cell cycle, become progenitors, and replace lost retinal neurons — fully restoring vision. This is the biological proof that a complete retinal-regeneration program exists in the vertebrate lineage, and the blueprint researchers are switching on in mammals.

Adult retinal cells coaxed into new neurons. Thomas Reh’s lab at the University of Washington showed that switching on the proneural factor Ascl1 drives mouse — and human — Müller glia to become neurogenic and form new retinal neurons (Jorstad et al., Nature, 2017; human work in Stem Cell Reports, 2023).

Blind mice see after the retina regrows its own rods. Bo Chen’s NEI-funded team at the Icahn School of Medicine at Mount Sinai reprogrammed Müller glia into functional rod photoreceptors inside living mice — without injuring the retina first — restoring vision in congenitally blind mice (Nature, 2018).

Research & institutions: Thomas Reh’s lab at the University of Washington, Daniel Goldman’s and Pamela Raymond’s labs at the University of Michigan, Bo Chen’s Ocular Stem Cell Program at the Icahn School of Medicine at Mount Sinai, Andy Fischer at the Ohio State University, Seth Blackshaw at Johns Hopkins University, Constance Cepko at Harvard Medical School, Rachel Wong at the University of Washington, the National Eye Institute Audacious Goals Initiative, the Foundation Fighting Blindness, RIKEN, and the broader Müller-glia retinal-regeneration field.

Demonstrated components (today): the human retina holds the same repair cell as fish, yet it stays quiet because mammalian Müller glia are held back by internal molecular brakes. Those suppressive signals are real and increasingly mapped — identifying them is the foundation for releasing them, and it works entirely through the retina’s own cells.

The capability being built toward: finding and safely releasing those brakes — not by adding stem cells or growth factors, but by removing the signals that suppress the retina’s own latent program. When fully built, this would be the cleanest possible lever, restarting regeneration through the retina’s own biology alone. The brakes are demonstrated and the latent program is real today; releasing them safely in the human retina, without overshoot, is the direction and the frontier.

Suppressive signaling that blocks Müller-glia reprogramming, including intercellular transfer of the factor Prox1, and the gene-regulatory brakes that distinguish quiet mammalian glia from regenerating fish glia — targets to release, not replace.

The brake, identified and lifted. A team at the Korea Advanced Institute of Science and Technology (KAIST) showed that the factor Prox1, passed from neighboring neurons into Müller glia, is a key brake on mammalian retinal repair — it builds up in degenerating human and mouse retinas but not in regenerating zebrafish. Blocking its transfer with a delivered anti-Prox1 antibody let mouse Müller glia begin reprogramming into retinal progenitors and delayed vision loss in a retinitis-pigmentosa model — regeneration achieved by removing a brake, not adding cells (Nature Communications, 2025).

A second brake, mapped across species. Seth Blackshaw’s lab at Johns Hopkins University, with an international team, compared regenerating zebrafish and chick retinas against non-regenerating mouse retinas and found that mammals run a dedicated gene network that actively suppresses regeneration; disrupting those nuclear-factor-I (NFI) brakes made adult mouse Müller glia proliferate and generate new neurons after injury (Hoang et al., Science, 2020).

The capacity was silenced, not lost. Together these results support a powerful idea: the retina’s — and perhaps the wider nervous system’s — regenerative program may not be gone, only suppressed, and therefore re-openable.

Research & institutions: Jin Woo Kim’s lab at the Korea Advanced Institute of Science and Technology (KAIST), Thomas Reh and the University of Washington, Daniel Goldman and the University of Michigan, Seth Blackshaw at Johns Hopkins University, the University of Utah, Andy Fischer at the Ohio State University, Bo Chen at Mount Sinai, the National Eye Institute Audacious Goals Initiative, the Foundation Fighting Blindness, RIKEN, and the broader retinal gene-regulation and reprogramming field.

Demonstrated components (today): making a new retinal cell is only half the work — it has to become the right cell and wire into the right place. The retina’s reprogramming instructions are being read in detail, and in fish this faithful rewiring of regrown neurons into the precise visual circuit happens naturally. That natural fish precedent is demonstrated. Shared with neuroregeneration.

The capability being built toward: using those instructions to guide reawakened glia to become the needed neurons, then ensuring those neurons connect correctly into the retina’s precise circuit so the regrown tissue actually carries sight. When fully built, it would reproduce in the mammalian retina the faithful wiring fish achieve naturally. The reprogramming instructions and the fish precedent are real today; achieving correct cell-type identity and circuit wiring in the mammalian retina is an honest frontier.

Retinal epigenetics and the DNA-methylation and transcription-factor program of reprogramming, photoreceptor and neuron subtype specification, synaptic integration, and faithful retinotopic wiring — the instructions and connections that turn new cells into working vision.

The reprogramming instructions, decoded. Seth Blackshaw at Johns Hopkins University and Thomas Reh at the University of Washington mapped the gene-regulatory and epigenetic steps — the chromatin and DNA-methylation changes and the proneural factors — that let Müller glia reprogram, defining the instruction set needed to guide mammalian regeneration safely and in order.

From glia to the specific neuron a disease has lost. Levi Todd and Thomas Reh at the University of Washington combined developmental transcription factors (Ascl1 with Atoh1) to push adult mouse Müller glia to become retinal-ganglion-like cells with the right electrical responses — a step toward regenerating the exact cell a given disease destroys, not just any neuron (Science Advances, 2022).

Wiring is the test of success. Rachel Wong at the University of Washington, who images how retinal neurons assemble into circuits, and zebrafish-regeneration researchers have shown that regenerated neurons can re-form the retina’s circuit organization in fish; reproducing that faithful wiring in the mammalian retina is the frontier that decides whether regrown cells become usable sight.

Research & institutions: Thomas Reh and the University of Washington, Daniel Goldman and the University of Michigan, Seth Blackshaw at Johns Hopkins University, Constance Cepko at Harvard Medical School, Rachel Wong’s retinal-circuit research at the University of Washington, Andy Fischer at the Ohio State University, Michael Dyer at St. Jude Children’s Research Hospital, the National Eye Institute Audacious Goals Initiative, the Foundation Fighting Blindness, RIKEN, and the broader retinal-reprogramming and circuit-wiring field.

Demonstrated components (today): human stem cells can be grown into retinal tissue containing real, light-responsive photoreceptors — a proven replacement source built from the body’s own biology. This works in the lab today, offering new light-sensing cells when degeneration has taken too many of the retina’s own to reawaken. Shared with vision restoration.

The capability being built toward: using these lab-grown cells to rebuild what was lost when in-place regeneration is no longer possible, and delivering them without an invasive procedure. When fully built, it would restore the retina from the body’s own grown tissue. The light-responsive photoreceptors grown from stem cells are real and demonstrated today; delivering them into the retina is still early research, and doing so noninvasively is the direction and frontier.

Human pluripotent stem-cell–derived retinal organoids, photoreceptor differentiation, light-responsive cone and rod generation, and synapse-forming replacement tissue — a lab-stage source of new light-sensing cells.

Working retinas grown from human cells. David Gamm’s lab at the University of Wisconsin–Madison grew 3D “mini-retinas” from human stem cells containing photoreceptors that respond to light like real cones and reach out to form new synaptic connections — a potential replacement-cell source for restoring lost vision (Cell Stem Cell, 2022; PNAS, 2023).

The first patient’s own cells, returned to the eye. Masayo Takahashi’s team at RIKEN performed the first transplant of retinal cells made from a patient’s own iPS cells — for macular degeneration, in 2014 — an early proof that retinal tissue grown from the body’s own biology can be safely returned to a human eye.

Replacement cells, already in patients. Henry Klassen’s team at the University of California, Irvine (jCyte) has tested injectable retinal progenitor cells in people with retinitis pigmentosa, and the London Project to Cure Blindness (Pete Coffey and Lyndon da Cruz, University College London and Moorfields) implanted stem-cell-derived retinal cells in patients with macular degeneration — the first steps from lab to people.

Research & institutions: David Gamm’s lab at the University of Wisconsin–Madison, Masayo Takahashi at RIKEN, Henry Klassen at the University of California, Irvine (jCyte), the London Project to Cure Blindness (Pete Coffey and Lyndon da Cruz, UCL and Moorfields), Robin Ali’s retinal cell-therapy research, Kapil Bharti at the National Eye Institute, BlueRock Therapeutics, Lineage Cell Therapeutics, Opsis Therapeutics, the Foundation Fighting Blindness, the California Institute for Regenerative Medicine, and the broader retinal-organoid and photoreceptor-replacement field.

Demonstrated components (today): the true measure of retinal regeneration is not new cells but restored vision — light detected, an image rebuilt and carried to the brain, and the brain re-learning to use it. The individual pieces are understood: regrown and replacement neurons must wire into the visual pathway, and the visual system must adapt to the restored signal, drawing on the brain’s known capacity to relearn.

The capability being built toward: functional sight from the retina’s own biology and not from any device — the north star, and the link to vision restoration and the unified complete vision capability. When fully built, it would deliver regrown and replacement neurons wired into the visual pathway with the brain adapting to use them. The component requirements are understood today; uniting wiring, adaptation, and relearning into restored functional sight is the frontier this capability points toward.

Synaptic integration of regenerated and replacement neurons, visual-pathway reconnection, retinotopic targeting, and cortical plasticity and visual re-learning — the steps that convert regrown cells into usable sight.

A public goal, named. The National Eye Institute’s Audacious Goals Initiative is a sustained federal program whose explicit aim is to restore vision by regenerating the retina’s neurons and their connections to the brain — the clearest statement that functional sight, not just new cells, is the target.

The brain can learn to use restored signals. Work led by Pawan Sinha at MIT (Project Prakash) showed the visual brain stays plastic and can learn to see even after long blindness — evidence that once regenerated cells deliver a signal, the brain can adapt to use it as sight.

Restoring sight after injury. The U.S. Department of Defense Vision Research Program (CDMRP) funds restoring visual function after retinal injury, advancing the same end goal of usable vision recovered from the body’s own biology.

Research & institutions: the National Eye Institute Audacious Goals Initiative, the Department of Defense Vision Research Program (CDMRP), Pawan Sinha’s Project Prakash at the Massachusetts Institute of Technology, Mass Eye and Ear, the Foundation Fighting Blindness, Stanford University, the Wilmer Eye Institute at Johns Hopkins, University College London and Moorfields Eye Hospital, the University of Washington, RIKEN, and the broader vision-restoration and visual-plasticity field.